Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.40−0.64 (-4.91%)
Close on Nov 18, 2026Market cap $460.59MP/E –Yield –
Crescent Biopharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Crescent Biopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$73.62M. For fiscal 2025 it was -$72.45M. The highest annual figure on record is -$4.49M in fiscal 2014.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$72.45M | – |
| FY2024 | Dec 31, 2024 | -$31.11M | – |
| FY2023 | Dec 31, 2023 | -$34.90M | – |
| FY2022 | Dec 31, 2022 | -$46.54M | – |
| FY2021 | Dec 31, 2021 | -$57.50M | – |
| FY2020 | Dec 31, 2020 | -$39.31M | – |
| FY2019 | Dec 31, 2019 | -$52.13M | – |
| FY2018 | Dec 31, 2018 | -$43.46M | – |
| FY2017 | Dec 31, 2017 | -$30.06M | – |
| FY2016 | Dec 31, 2016 | -$30.44M | – |
| FY2015 | Dec 31, 2015 | -$8.51M | – |
| FY2014 | Dec 31, 2014 | -$4.49M | – |
| FY2013 | Dec 31, 2013 | -$15.62M | – |
| FY2012 | Dec 31, 2012 | -$10.79M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$26.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.13M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.70M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.52M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.69M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.27M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.52M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.51M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.47M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.47M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.39M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.04M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.11M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.23M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.40M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.26M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.27M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.12M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.39M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.70M | – |
See a number that looks wrong?